Top 20 Biopharma Deal Terminations of 2023 Based on Total Deal Value

Top 20 Biopharma Deal Terminations of 2023 Based on Total Deal Value

Using DealForma insights, PharmaShots highlights the Top 20 Biopharma Deal Terminations of 2023, led by the $3.75B Janssen–Arrowhead split. Read it here

DealForma Research

Explore More
AI-ML Drug Discovery and Licensing R&D, M&A, Ventures and IPOs - 2025 Review

AI-ML Drug Discovery and Licensing R&D, M&A, Ventures and IPOs – 2025 Review

Infectious R&D Partnerships, M&A and Venture Funding - Q3 2025 Review

Infectious R&D Partnerships, M&A and Venture Funding – Q3 2025 Review

Endocrine-Metabolic R&D Partnerships, M&A and Venture Funding - Q3 2025 Review

Endocrine-Metabolic R&D Partnerships, M&A and Venture Funding – Q3 2025 Review

All of this by stage, disease indication, modality, target…

Schedule your Demo
+ 0 k
Licensing Deals
+ 0 k
M&A
+ 0 k
Other Deals
+ 0 k
Funding Rounds
+ 0 k
Company Profiles
+ 0 k
Drug Sales Figures
DealForma Logo

DealForma is the biopharma deal database providing you comprehensive information and dedicated analyst support to help you be more confident using quality data in your business development research.

Linkedin

Database

Company

Comparisons

Website Design by Once Interactive